NNOX
Bearish signal
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Financial indicators Unavailable or mixed. Current ratio 3.96 · operating margin -466% — readings disagree
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
ACHAT TOTAL: 83 000 titres (~76 700,00 $ US)
- Insiders
- Suesskind Dan SKainan Noga
- Total bought
-
$76,700
Avg buy (VWAP, 90d window) $0.85 vs last close —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
- Last activity
- 2026-07-28
- Last synced
-
2026-08-03 10:19:38
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-14 | Suesskind Dan S | Buy | 30,000 | $0.75 | $22,500 | Form 4 |
| 2026-07-28 | Kainan Noga | Buy | 33,000 | $0.90 | $29,700 | Form 4 |
| 2026-07-27 | Suesskind Dan S | Buy | 25,000 | $0.92 | $23,000 | Form 4 |
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Market snapshot
Signal
Bearish signalScored 2026-08-03
NNOX presents a deeply unfavorable risk/reward profile: severe fundamental distress (persistent operating losses, negative margins, and cash burn) overwhelms a modest liquidity cushion, yielding a weak financial…
The first sentence of the analysis written for NNOX on 2026-08-03 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | -98.2% | -94.0% | -66.6% | -80.2% | -116.0% | |
| Ebit Margin | -466.2% | -502.9% | -602.3% | -1016.6% | -4720.7% | |
| Ebitda Margin | -376.3% | -398.9% | -481.5% | -882.4% | -4544.9% | |
| Operating Profit Margin | -466.2% | -502.9% | -631.9% | -1279.0% | -4720.7% | |
| Pretax Profit Margin | -589.9% | -477.5% | -617.0% | -1269.8% | -4742.8% | |
| Continuous Operations Profit Margin | -576.1% | -474.3% | -613.6% | -1320.2% | -4739.1% | |
| Net Profit Margin | -576.1% | -474.3% | -613.6% | -1226.9% | -4739.1% | |
| Bottom Line Profit Margin | -576.1% | -474.3% | -613.6% | -1320.2% | -4739.1% | |
| Current Ratio | 3.955 | 5.631 | 5.710 | 3.289 | 1.798 | |
| Quick Ratio | 3.773 | 5.524 | 5.558 | 3.192 | 1.739 | |
| Solvency Ratio | -2.823 | -2.001 | -2.117 | -2.516 | -0.838 | |
| Cash Ratio | 2.910 | 2.813 | 3.632 | 1.534 | 1.263 | |
| Price To Earnings Ratio | -2.414 | -7.912 | -5.898 | -3.672 | -11.359 | |
| Price To Earnings Growth Ratio | -0.088 | 0.503 | 0.127 | -0.064 | -2.310 | |
| Forward Price To Earnings Growth Ratio | -0.088 | 0.503 | 0.127 | -0.064 | -2.310 | |
| Price To Earnings Diluted Ratio | -2.414 | -7.912 | -5.898 | -3.672 | -11.359 | |
| Price To Earnings Diluted Growth Ratio | -0.088 | 0.503 | 0.127 | -0.064 | -2.310 | |
| Price To Book Ratio | 1.298 | 2.232 | 1.837 | 1.779 | 2.400 | |
| Price To Sales Ratio | 13.932 | 37.410 | 36.251 | 44.940 | 537.623 | |
| Price To Free Cash Flow Ratio | -4.031 | -10.723 | -7.468 | -7.625 | -11.450 | |
| Price To Operating Cash Flow Ratio | -4.447 | -11.533 | -8.019 | -8.885 | -18.415 | |
| Debt To Assets Ratio | 0.048 | 0.035 | 0.038 | 0.018 | 0.016 | |
| Debt To Equity Ratio | 0.056 | 0.039 | 0.043 | 0.021 | 0.020 | |
| Debt To Capital Ratio | 0.053 | 0.038 | 0.041 | 0.021 | 0.019 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.016 | 0.013 | |
| Financial Leverage Ratio | 1.161 | 1.110 | 1.118 | 1.172 | 1.243 | |
| Working Capital Turnover Ratio | 0.227 | 0.164 | 0.152 | 0.172 | 0.010 | |
| Operating Cash Flow Ratio | -2.416 | -2.619 | -2.884 | -1.730 | -0.722 | |
| Operating Cash Flow Sales Ratio | -3.133 | -3.244 | -4.521 | -5.058 | -29.196 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.103 | 1.076 | 1.074 | 1.165 | 1.608 | |
| Debt Service Coverage Ratio | -15.054 | -14.588 | -13.568 | 0.000 | -136.762 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | -213.743 | |
| Short Term Operating Cash Flow Coverage Ratio | -13.008 | -11.956 | -12.830 | 0.000 | -262.559 | |
| Operating Cash Flow Coverage Ratio | -5.196 | -4.915 | -5.333 | -9.393 | -6.596 | |
| Capital Expenditure Coverage Ratio | -9.696 | -13.227 | -13.556 | -6.050 | -1.644 | |
| Dividend Paid And Capex Coverage Ratio | -9.696 | -13.227 | -13.556 | -6.050 | -1.644 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -2.859 | -8.669 | -6.523 | -4.646 | -10.802 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | -98.2% | ▼-4.2% | ▼-7.2% |
| Ebit Margin | -466.2% | ▲36.8% | ▲995.6% |
| Ebitda Margin | -376.3% | ▲22.6% | ▲960.5% |
| Operating Profit Margin | -466.2% | ▲36.8% | ▲1054.0% |
| Pretax Profit Margin | -589.9% | ▼-112.4% | ▲949.5% |
| Continuous Operations Profit Margin | -576.1% | ▼-101.8% | ▲968.5% |
| Net Profit Margin | -576.1% | ▼-101.8% | ▲949.9% |
| Bottom Line Profit Margin | -576.1% | ▼-101.8% | ▲968.5% |
| Current Ratio | 3.955 | ▼-1.676 | ▼-0.121 |
| Quick Ratio | 3.773 | ▼-1.751 | ▼-0.184 |
| Solvency Ratio | -2.823 | ▼-0.822 | ▼-0.764 |
| Cash Ratio | 2.910 | ▲0.097 | ▲0.480 |
| Price To Earnings Ratio | -2.414 | ▲5.498 | ▲3.837 |
| Price To Earnings Growth Ratio | -0.088 | ▼-0.591 | ▲0.279 |
| Forward Price To Earnings Growth Ratio | -0.088 | ▼-0.591 | ▲0.279 |
| Price To Earnings Diluted Ratio | -2.414 | ▲5.498 | ▲3.837 |
| Price To Earnings Diluted Growth Ratio | -0.088 | ▼-0.591 | ▲0.279 |
| Price To Book Ratio | 1.298 | ▼-0.934 | ▼-0.611 |
| Price To Sales Ratio | 13.932 | ▼-23.477 | ▼-120.099 |
| Price To Free Cash Flow Ratio | -4.031 | ▲6.691 | ▲4.228 |
| Price To Operating Cash Flow Ratio | -4.447 | ▲7.086 | ▲5.813 |
| Debt To Assets Ratio | 0.048 | ▲0.013 | ▲0.017 |
| Debt To Equity Ratio | 0.056 | ▲0.017 | ▲0.020 |
| Debt To Capital Ratio | 0.053 | ▲0.015 | ▲0.019 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | ▼-0.006 |
| Financial Leverage Ratio | 1.161 | ▲0.050 | ▼-0.000 |
| Working Capital Turnover Ratio | 0.227 | ▲0.064 | ▲0.082 |
| Operating Cash Flow Ratio | -2.416 | ▲0.204 | ▼-0.341 |
| Operating Cash Flow Sales Ratio | -3.133 | ▲0.111 | ▲5.897 |
| Free Cash Flow Operating Cash Flow Ratio | 1.103 | ▲0.028 | ▼-0.102 |
| Debt Service Coverage Ratio | -15.054 | ▼-0.466 | ▲20.940 |
| Interest Coverage Ratio | 0.000 | 0.000 | ▲42.749 |
| Short Term Operating Cash Flow Coverage Ratio | -13.008 | ▼-1.052 | ▲47.063 |
| Operating Cash Flow Coverage Ratio | -5.196 | ▼-0.281 | ▲1.091 |
| Capital Expenditure Coverage Ratio | -9.697 | ▲3.530 | ▼-0.862 |
| Dividend Paid And Capex Coverage Ratio | -9.697 | ▲3.530 | ▼-0.862 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -2.859 | ▲5.810 | ▲3.840 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $181.4M | $422.1M | $359.1M | $385.5M | $701.1M | |
| Enterprise value | $140.1M | $390.2M | $311.1M | $351.7M | $640.2M | |
| EV / Sales | 10.76x | 34.59x | 31.41x | 40.99x | 490.94x | |
| EV / Op. cash flow | -3.44x | -10.66x | -6.95x | -8.11x | -16.82x | |
| EV / Free cash flow | -3.11x | -9.91x | -6.47x | -6.96x | -10.46x | |
| EV / EBITDA | -2.86x | -8.67x | -6.52x | -4.65x | -10.80x | |
| Net debt / EBITDA | 0.84x | 0.71x | 1.01x | 0.45x | 1.03x | |
| Current ratio | 3.96x | 5.63x | 5.71x | 3.29x | 1.80x | |
| Income quality | 0.54x | 0.68x | 0.74x | 0.41x | 0.62x | |
| Graham net-net | $1 | $1 | $1 | $1 | $0 | |
| Tax burden | 97.7% | 99.3% | 99.4% | 96.6% | 99.9% | |
| Interest burden | 126.5% | 94.9% | 102.4% | 124.9% | 100.5% | |
| Working capital | $49.9M | $64.7M | $73.1M | $57.4M | $42.1M | |
| Invested capital | $143.3M | $183.9M | $200.6M | $200.7M | $241.4M | |
| Return on assets | -46.3% | -25.5% | -27.8% | -41.4% | -17.0% | |
| Operating ROA | -32.6% | -26.5% | -26.5% | -35.6% | -20.5% | |
| Return on tangible assets | -73.6% | -38.2% | -44.0% | -67.8% | -30.4% | |
| Return on equity | -53.7% | -28.3% | -31.1% | -48.6% | -21.2% | |
| Return on invested capital | -39.7% | -28.2% | -30.0% | -46.2% | -19.7% | |
| Return on capital employed | -41.8% | -28.9% | -30.8% | -47.9% | -19.8% | |
| Earnings yield | -41.4% | -12.7% | -16.9% | -27.3% | -8.8% | |
| Free cash flow yield | -24.8% | -9.3% | -13.4% | -13.1% | -8.7% | |
| Capex / Op. cash flow | -10.3% | -7.6% | -7.4% | -16.5% | -60.8% | |
| Capex / Depreciation | 36.0% | 23.6% | 28.0% | 62.3% | 1010.4% | |
| Capex / Sales | 32.3% | 24.5% | 33.3% | 83.6% | 1775.9% | |
| SG&A / Sales | 208.1% | 228.2% | 286.7% | 531.9% | 3201.1% | |
| R&D / Sales | 147.7% | 178.9% | 263.0% | 309.0% | 1313.0% | |
| Stock comp / Sales | 32.2% | 64.4% | 69.0% | 217.1% | 1442.2% | |
| Intangibles / Total assets | 37.1% | 33.3% | 36.9% | 38.8% | 44.1% | |
| Days sales outstanding | 56d | 58d | 55d | 42d | 294d | |
| Days payables outstanding | 41d | 37d | 73d | 85d | 406d | |
| Operating cycle | 100d | 83d | 107d | 99d | 700d | |
| Cash conversion cycle | 59d | 46d | 34d | 13d | 294d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-57.0%EV / Sales ▼-68.9%EV / EBITDA ▲+67.0%EV / Op. cash flow ▲+7.228Earnings yield ▼-0.287
Profitability
Return on equity ▼-0.254Return on assets ▼-0.208Return on invested capital ▼-0.115Return on capital employed ▼-0.128Operating ROA ▼-0.061Income quality ▼-0.140Tax burden ▼-0.017
Efficiency
Days sales outstanding ▼-1.963Days payables outstanding ▲+3.985Operating cycle ▲+16.561Cash conversion cycle ▲+12.577Capex / Sales ▲+0.078R&D / Sales ▼-0.311
Balance-sheet strength
Current ratio ▼-1.676Net debt / EBITDA ▲+0.135Working capital ▼-14803000.000Invested capital ▼-40617000.000Intangibles / Total assets ▲+0.038
Change over 5 years
Valuation
Market cap ▼-74.1%EV / Sales ▼-97.8%EV / EBITDA ▲+73.5%EV / Op. cash flow ▲+13.381Earnings yield ▼-0.325
Profitability
Return on equity ▼-0.325Return on assets ▼-0.292Return on invested capital ▼-0.199Return on capital employed ▼-0.220Operating ROA ▼-0.121Income quality ▼-0.072Tax burden ▼-0.023
Efficiency
Days sales outstanding ▼-237.756Days payables outstanding ▼-365.403Operating cycle ▼-599.909Cash conversion cycle ▼-234.505Capex / Sales ▼-17.436R&D / Sales ▼-11.653
Balance-sheet strength
Current ratio ▲+2.157Net debt / EBITDA ▼-0.184Working capital ▲+7799000.000Invested capital ▼-98106000.000Intangibles / Total assets ▼-0.070
Employee count
Peer market caps
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent news
- 2026-08-02 NNOX SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Nano-X Imaging (NNOX) Investors of Securities Class Action Lawsuit Deadline on August 11, 2026 Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nano-X To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Nano-X between March 31, 2025 and April 17, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - August 2, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Nano-X Imaging Ltd.
- 2026-08-02 Bronstein, Gewirtz & Grossman LLC Urges Nano-X Imaging Ltd. Investors to Act: Class Action Filed Alleging Investor Harm New York, New York--(Newsfile Corp. - August 2, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Nano-X Imaging Ltd. (NASDAQ: NNOX) and certain of its officers.
- 2026-08-02 NNOX DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Nano-X Imaging Ltd. Investors to Secure Counsel Before Important August 11 Deadline in Securities Class Action - NNOX New York, New York--(Newsfile Corp. - August 2, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nano-X Imaging Ltd. (NASDAQ: NNOX) between March 31, 2025 and April 17, 2026, inclusive (the "Class Period"), of the important August 11, 2026 lead plaintiff deadline.
- 2026-08-01 NNOX Deadline: Rosen Law Firm Urges Nano-X Imaging Ltd. (NASDAQ: NNOX) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights Rosen Law Firm, a global investor rights law firm, reminds investors about a class action lawsuit on behalf of purchasers of securities of Nano-X Imaging Ltd. (
- 2026-08-01 NNOX Deadline: Rosen Law Firm Urges Nano-X Imaging Ltd. (NASDAQ: NNOX) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors about a class action lawsuit on behalf of purchasers of securities of Nano-X Imaging Ltd. (NASDAQ: NNOX) between March 31, 2025 and April 17, 2026. Nano-X describes itself as a company that “develops a commercial-grade tomographic imaging device with a digital X-ray source.”For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653.The Allegations: Rosen Law Fir.
- 2026-08-01 NNOX DEADLINE ALERT: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Nano-X Imaging Ltd. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 11 Deadline in Securities Class Action – NNOX NEW YORK, Aug. 01, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nano-X Imaging Ltd. (NASDAQ: NNOX) between March 31, 2025 and April 17, 2026, inclusive (the “Class Period”), of the important August 11, 2026 lead plaintiff deadline.
- 2026-07-31 NNOX FINAL DEADLINE: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Nano-X Imaging Ltd. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 11 Deadline in Securities Class Action - NNOX New York, New York--(Newsfile Corp. - July 31, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nano-X Imaging Ltd. (NASDAQ: NNOX) between March 31, 2025 and April 17, 2026, inclusive (the "Class Period"), of the important August 11, 2026 lead plaintiff deadline.
- 2026-07-31 NNOX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Nano-X Imaging (NNOX) Investors of Securities Class Action Lawsuit Deadline on August 11, 2026 Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nano-X To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Nano-X between March 31, 2025 and April 17, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - July 31, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Nano-X Imaging Ltd.
- 2026-07-31 NNOX UPCOMING DEADLINE : The Gross Law Firm Alerts Nano-X Imaging Ltd. Stockholders of Securities Class Action - Contact the Firm NEW YORK, July 31, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Nano-X Imaging Ltd. (NASDAQ: NNOX).
- 2026-07-30 NNOX Deadline: NNOX Investors Have Opportunity to Lead Nano-X Imaging Ltd. Securities Fraud Lawsuit NEW YORK, July 30, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nano-X Imaging Ltd. (NASDAQ: NNOX) between March 31, 2025 and April 17, 2026, inclusive (the "Class Period"), of the important August 11, 2026 lead plaintiff deadline.